Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This report describes a patient with an intramedullary ependymoma at the region of the cervicomedullary junction in whom there was an abolition of somatosensory evoked potentials following median nerve stimulation. During intraoperative monitoring of cortical potentials elicited by epidural cervical cord stimulation, the tumor was removed. Posterior epidural stimulation appeared to depolarize more ascending fibers than did stimulation of a single peripheral nerve. We recommend that, in cases of operations in this vital area, epidurally evoked cortical potentials be monitored intraoperatively.
J Clin Monit 1991 Jan
PMID:Usefulness of epidurally evoked cortical potential monitoring during cervicomedullary glioma surgery. 199 96

Hypoglycemia induced by surreptitious sulfonylurea ingestion can be difficult to distinguish from an insulin-secreting tumor. We describe a technique for detecting most of the common sulfonylurea drugs in plasma. After preliminary acidification, and extraction in ether, the residue is reconstituted and injected onto a Versapack high-performance liquid chromatography column. Detection is at 230 nm. This procedure gives good separation of chlorpropamide, glibenclamide, gliclazide, glipizide, and tolbutamide. Results are semiquantitative but the sensitivity of the assay is sufficient to detect and identify clinically active concentrations of all five drugs. It is a rapid and reliable screening test. Four representative case histories are reported in which the screen proved to be of diagnostic value.
Ther Drug Monit 1990 Jul
PMID:A screening test for detecting sulfonylureas in plasma. 211 93

The aim of this study was to find appropriate somatosensory evoked potential (SSEP) and tumor data that would predict immediate postoperative outcome. Seventeen patients were evaluated, all with supratentorial mass lesions. Intraoperative SSEP monitoring was carried out, and central conduction time, N20 amplitude, and N20 to N13 amplitude ratio were recorded throughout the operation. The differences between the end and the start of the procedure and between the end of the operation and the most substantial changes during tumor removal were calculated for statistical evaluation. Tumor location and extent were carefully determined and calculated by computed tomographic reconstructions in the axial and sagittal planes. Several tumor parameters were measured: the distances from the midpoint of the tumor to the central sulcus, midline, and base of the skull and the longitudinal and cross-sectional diameters. The electrophysiologic and tumor data sets were correlated with the immediate postoperative neurologic deterioration. For this purpose, patients were divided into two groups: group 1 = no neurologic deterioration after operation (13 patients); group 2 = neurologic deterioration after operation (4 patients). The difference in central conduction times between the end and the start of the procedure was the only variable that exhibited a significant influence on the immediate postoperative condition (P = 0.007), as determined by analysis of variance. The other electrophysiologic data as well as the tumor data failed the significance threshold of P = 0.05. Discriminant analysis was applied to test the classification capacity of the measured variables. Involving all measured variables (electrophysiologic and tumor data), discriminant analysis allowed a correct classification of all 17 patients to their proper neurologic deterioration group. Discriminant analysis for SSEP data alone led to 15 correct classifications. Tumor data, used alone for discriminating procedures, revealed 14 correct classifications. When each variable was analyzed separately, only the difference in central conduction times between the end and the start of the procedure gave significant predictions, namely, 15 correct classifications. This was the same number as achieved by all electrophysiologic variables together. No other variable could on its own yield any valid prognosis for assessment of immediate postoperative neurologic deterioration. The data confirm the importance of central conduction time recovery before the end of the operation on the patient's immediate postoperative neurologic condition.
J Clin Monit 1990 Apr
PMID:The prognostic value of somatosensory evoked potential monitoring and tumor data in supratentorial tumor removal. 235 6

Dexamethasone in plasma and in tissue is specifically quantitated by high performance liquid chromatography (ultraviolet detection at 254 nm) with an octadecyl silane reversed-phase chromatographic column employing peak-height ratio determination (internal standard, cyheptamide). The sample is first washed with heptane under alkaline conditions. The dexamethasone is then extracted from the washed sample with dichloromethane containing the internal standard. Dichloromethane is evaporated to dryness, and the concentrated extract is dissolved in tetrahydrofuran and then injected into a high performance liquid chromatograph. Dexamethasone and internal standard are eluted with a mixture of acetic acid, methanol, butanol, and water (11/19/30/440 by volume). Sensitivity limit is 10 ng, with linear response to at least 1.000 mg/liter plasma. Analytical recovery of dexamethasone from plasma is almost complete, and approximately 87% dexamethasone is recovered from brain tissue. Intra-assay precision (CV) is 1.07% (N = 11), and interassay precision is 1.38% (N = 5). No interference occurred in plasmas from patients treated with various drugs other than dexamethasone. Dexamethasone was estimated in plasma and in tumor tissue from patients on dexamethasone therapy.
Ther Drug Monit 1980
PMID:High performance liquid chromatographic assay of dexamethasone in plasma and tissue. 722 92

Fostriecin is an antitumor antibiotic with marked activity against ovarian, breast, and lung cancer cell lines in the human tumor clonogenic assay. The mechanism of cytotoxicity in vivo is unknown; in vitro it has been shown to inhibit macromolecular synthesis, interact with the reduced folate carrier system, and inhibit topoisomerase II. Phase I testing of fostriecin in a daily for 5 days schedule has begun in cancer patients. A high-pressure liquid chromatographic method to measure fostriecin in plasma samples was developed using sulfaquinoxaline as an internal standard and ultraviolet detection (268 nm). The extraction efficiency is 70% and the sensitivity limit is 100 ng/ml. The pharmacokinetics of fostriecin were determined in six rabbits following intravenous injection of 12 mg/m2. The mean distribution space was 4.44 L/m2 and the mean plasma clearance was 302 ml/min/m2. The elimination half-life was 11.95 +/- 8.55 min. All rabbits exhibited a 10-60-fold increase in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) that resolved within 48 h of drug administration.
Ther Drug Monit 1994 Apr
PMID:Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. 800 68

5-Fluorouracil (FU) is metabolized by dihydropyrimidine dehydrogenase (DPD). Patients with suspected or proven DPD deficiency develop more or less severe FU-related side effects including death. In these reported cases, DPD activity in peripheral blood mononuclear cells (PBMC-DPD) was < 100 pmol/min/mg protein. A circadian rhythm in PBMC-DPD activity has been observed, with a peak at 1 a.m. and a trough at 1 p.m. on average. As a corollary, a circadian rhythm was observed in FU plasma concentration, with a peak at 11 a.m. and a trough at 11 p.m. on average. A significant relationship between PBMC-DPD activity and FU clearance was established but the link was weak (r = 0.31). Thus, a FU dose adaptation based on PBMC-DPD is not justified whereas a pharmacokinetically based FU dose adaptation is recommended. Experimental studies have shown that DPD activity in tumor cell lines is related to FU cytotoxicity. Although resistance to FU depends on many factors, recent clinical studies in head and neck cancer patients treated by FU suggest that tumoral DPD activity is a determining factor in predicting FU-responsiveness.
Ther Drug Monit 1996 Aug
PMID:Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. 885 47

Agents (modulators) that reverse the in vitro resistance of tumor cells to anticancer drugs that are substrates for P-glycoprotein (Pgp, the product of the MDR1 gene) have been given to patients concurrently with anticancer drugs in an attempt to improve therapeutic response. The vast majority of investigations into these drugs indicate that Pgp modulators decrease the systemic clearance of anticancer drugs, thus potentially nonselectively increasing exposure to normal and malignant cells and thereby potentially increasing the severity and/or incidence of adverse effects associated with the anticancer therapy. Mechanisms by which Pgp modulators could alter the pharmacokinetics of the anticancer agent include competition for cytochrome P450 intestinal or liver metabolism, inhibition of Pgp-mediated biliary excretion or intestinal transport, or inhibition of renal elimination. It is suggested that administration of Pgp modulators is unlikely to improve the therapeutic index for anticancer drugs unless agents that lack significant pharmacokinetic interactions are found. Moreover, it will likely be required that there be some cancer-tissue selectivity for modulators in order to avoid collaterally increasing the sensitivity of normal Pgp-expressing tissues to the anticancer drug.
Ther Drug Monit 1996 Aug
PMID:Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? 885 49

Phenylacetate and phenylbutyrate, two novel inducers of tumor cytostasis and differentiation, are currently in clinical trials for the treatment of cancer in adults. The purpose of our study was to evaluate the plasma protein-binding characteristics of phenylacetate and phenylbutyrate in the plasma of normal volunteers and that of patients with cancer. Drug plasma protein-binding analysis was examined using three separate devices: a micropartition system and two equilibrium dialysis systems, all of which exhibited similar results. Phenylacetate and phenylbutyrate concentrations were determined by high-performance liquid chromatography. Both drugs exhibited concentration-dependent binding. Our results showed sodium phenylacetate to have a higher free fraction than sodium phenylbutyrate at corresponding concentrations (> 0.442 +/- 0.008 and > 0.188 +/- 0.001, respectively). Plasma pH did not greatly affect protein binding of either drug. As albumin concentration decreased, an increase in free fraction of both drugs was observed, however alpha 1-acid glyco-protein showed no change in free fraction as its concentration increased. Patients with cancer with lower levels of albumin showed an increase in free fraction with both phenylacetate and phenylbutyrate. When phenylacetate and phenylbutyrate were added together in plasma, the free fraction of phenylacetate increased, whereas the phenylbutyrate free fraction slightly decreased. We conclude that phenylacetate and phenylbutyrate have high free fractions that change with varying albumin levels and when both phenylacetate and phenylbutyrate are present together in plasma.
Ther Drug Monit 1996 Dec
PMID:Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents. 894 71

Several lipophilic, cytotoxic drugs, or both, (including anticancer drugs [Vinca alkaloids, doxorubicin, cyclosporin A, and digoxin]) have proven to be actively effluxed by P-glycoprotein (P-gp) expressed at the luminal membrane of the brain capillary endothelial cells, resulting in the very low apparent blood-brain barrier (BBB) permeation of these P-gp substrates from the blood circulating to the brain. In rats inoculated with 9L-glioma cells into the brain, the endothelial cells of tumor-associated vessels allowed easy penetration of anticancer drugs (ranimustine and doxorubicin) in tumor regions, although the normal BBB function still operated at the normal brain region to provide a barrier to the accumulation of P-gp substrates. A detailed knowledge of the BBB function would be very helpful in developing improved delivery systems of anticancer drugs to brain tumors.
Ther Drug Monit 1998 Oct
PMID:P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. 978 Jan 40

This paper reviews the toxicity and tumor-promoting properties of microcystins. Methods for screening and/or identification of microcystins in environmental samples are discussed and compared. Specific emphasis is placed on newly developed extraction/detection methods, e.g., solid phase microextraction (SPME) technique, and capillary electrophoresis coupled with laser-induced fluorescence detection. The results of a kinetic analysis of the effects of microcystins on phosphorylase-a binding to phosphatase-2A using a surface plasmon resonance biosensor are also presented.
Ther Drug Monit 2000 Feb
PMID:Toxicology and evaluation of microcystins. 1068 63


1 2 3 4 5 6 7 8 9 10 Next >>